The real experience of taking ribociclib/ribociclib for two consecutive years

Ribociclib is a selective CDK4/6 inhibitor mainly used to treat HR-positive, HER2-negative advanced or metastatic breast cancer. Many patients have a clear understanding of the drug's tolerance and efficacy during two years of continuous use. Judging from clinical feedback and patient interviews, most people said that the drug has a sustained and stable effect in disease control, especially when combined with aromatase inhibitors (such as letrozole), the inhibition of tumor growth is more significant. Imaging examinations of some patients show that the lesions are stable or even shrink, which delays the start of chemotherapy and improves the quality of life.

However, two years of continuous use is not completely free of side effects. Some patients experienced more common adverse reactions, such as neutropenia, fatigue, nausea, and mild liver function abnormalities. Most of these reactions appeared in the early stages of treatment, and some of them can be alleviated through dose reduction, intermittent medication, or symptomatic treatment. ECGQT interval prolongation is another concern, so most doctors will recommend regular monitoring of the ECG and electrolyte levels. In addition, some women may experience mood swings, decreased sleep quality, or mild hair loss during long-term medication. Although these effects do not constitute the main reason for discontinuing treatment, they still need to be actively addressed.

It is worth mentioning that psychological factors also play an important role in the long-term medication experience. Many patients said that the oral form of reboxil is more convenient than chemotherapy, which reduces the burden of frequent medical treatment. However, due to concerns about drug resistance or recurrence, emotional ups and downs are inevitable. Therefore, cooperation with psychological support and family care is also an important part of improving medication compliance. To sum up, the experience of taking Riboxil continuously for two years is generally positive. Its efficacy is stable and side effects are controllable. It has gained valuable treatment window and quality of life for some breast cancer patients.

Reference materials:https://us.kisqali.com/